| Reference |
Research population, setting and study period |
Study design and sample size |
Gender, age (mean ± SD) |
Diagnostic methods |
Prevalence of lipodystrophy |
| Santos CL et al. [16]. |
HIV/AIDS outpatients attending the Aids Hospital of the University of São Paulo Medical School, Brazil.
September to December 2001. |
Cross-sectional study
n=457 |
71.4% men.
Mean age 38 years, ranging between 19-74. |
Presence of symptoms subjectively reported by patients. |
64.3%
Lipohypertrophy=49.2%
Lipoatrophy=37.4%
Mixed=22.3% |
| Diehl LA et al.[17]. |
Patients attending the outpatient clinic of infectious diseases of the Clinical Hospital, State University of Londrina, Paraná, Brazil.
June 22 to November 23, 2006. |
Cross-sectional study
n=180 |
58.9% men.
Mean age 42.9 ± 10.5 years. |
Patient self-report and physician confirmation. |
55% |
| Monnerat BZ et al. [18]. |
Patients on Antiretroviral therapy recruited from the outpatient clinic at the University Hospital Cassiano Antonio de Morais, Vitória, Espírito Santo, Brazil.
July 2004 to May 2005. |
Retrospective cohort study
n=96 |
60.7% men.
Mean age 39.2 years. |
Patient self-report and physician confirmation. |
59.3% |
| De Carvalho EH et al. [19]. |
Patients attending the HIV/AIDS outpatient center, University Hospital Oswaldo Cruz, Recife, Pernambuco, Brazil.
July to December 2007. |
Cross-sectional study
n=256 |
62.1% men.
Mean age 41 ± 9.2 years. |
Presence of symptoms subjectively reported by patients. |
50.9% |
| Arruda Júnior EV et al. [20]. |
Patients attending the outpatient center of Oswaldo Cruz University Hospital, University of Pernambuco and the clinic center of CorreiaPicanço Hospital, state of Pernambuco, Brazil.
June 2007 to December 2008. |
Cross-sectional study
n=958 |
61% men.
Mean age 39.6 ± 10 years. |
Presence of symptoms subjectively reported by patients. |
47% (n=468) |
| Trinca JR et al. [21]. |
Patients attending the Hospital de Clínicas of Porto Alegre, Rio Grande do Sul, Brazil.
Unspecified study period. |
Cross-sectional study
n=410 |
54.6% men.
Mean age 43 ± 9.4 years. |
Presence of clinical signs observed on examination by a physician. |
53.4%
Lipohypertrophy=26.5%
Lipoatrophy=38.8%
Mixed=34.7% |
| Segatto AFM et al. [22]. |
Patients on antiretroviral therapy enrolled in the Counseling and Testing Center of PresidentePrudente, São Paulo, Brazil. |
Cross-sectional study
n=42 |
54.8% men.
Age ranged between 31 and 59 years. |
Patient self-report and physician confirmation. |
42.9% |
| Ceccato MGB et al. [23]. |
Medical records of patients on antiretroviral therapy treated at the Reference Center SagradaFamília, Belo Horizonte, Minas Gerais, Brazil.
From 2002 to 2006. |
Cross-sectional study
n=620 |
66.5% men.
Mean age 39.2 ± 9.9 years, ranging from 18 to 78 years. |
Presence of clinical signs observed on examination by a physician. |
32.4% |
| Gasparotto AS et al.[24]. |
Referral service for the treatment of HIV in three cities of Rio Grande doSul: Porto Alegre, Pelotas, and Rio Grande, Brazil. |
Cross-sectional study
n=614 |
55.5% men.
Mean age 42.6 ± 9.5 years. |
Presence of clinical signs observed on examination by a physician. |
51.1% (n=578)
Lipohypertrophy=25.3%
Lipoatrophy=42.1%
Mixed=32.6% |
| Signorini DJHP et al.[25]. |
Patients recruited from the Immunology Laboratory of the University Hospital GrafféeGuinles and the Federal University of Rio de Janeiro, Brazil.
January to May 2005. |
Cross-sectional study
n=819 |
54.6% men.
Mean age 41 ± 11 years. |
Patient self-report and physician confirmation. |
38.5% (n=727)
Lipohypertrophy=12.1%
Lipoatrophy=45.0%
Mixed=42.9% |
| Signorini DJHP et al. [26]. |
Patients on initial antiretroviral therapy, attending an outpatient center of a public hospital in Rio de Janeiro, Brazil.
November 2006 to October 2009. |
Cross-sectional study
n=187 |
73% men
Mean age 42 years. |
Patient self-report and physician confirmation. |
45.5% |
| Ponte CMM [27]. |
Patients recruited from the HIV/AIDS outpatient center for infectious diseases of São José Hospital, Fortaleza, Ceará, Brazil.
January to June 2010. |
Cross-sectional study
n=144 |
64.6% men
Mean age 42.1 ± 7.6 years. |
Patient self-report and physician confirmation. |
39.4%
Lipohypertrophy=14.6%
Lipoatrophy=28.8%
Mixed=14.4% |
| Soares LR [28] |
Secondary Immunodeficiency Outpatient Unit, Department of Dermatology, Hospital de Clínicas, University of São Paulo School of Medicine, Brazil.
June 2007 to December 2008. |
Cross-sectional
study
n=227 |
67% men
Mean age 42.7 ± 8.3, ranging from 20 to 66 years. |
Presence of symptoms subjectively reported by patients. |
40.5% |
| Freitas E[29] |
Patients recruited from a specialized care center of São Vicente, São Paulo, Brazil.
July 2010. |
Cross-sectional
study
n=130 |
43.1% men.
Mean age 42.3 ± 10.5 years. |
Patient self-report and physician confirmation. |
88.6%
Lipohypertrophy=34.4%
Lipoatrophy=7.5%
Mixed=46.7% |
| Schuelter-Trevisol, F [30] |
Patients attending a specialized care center of the State Secretary of Health, the Parthenon Sanatorium Hospital, Porto Alegre, Rio Grande do Sul, Brazil.
From 2006 to 2008. |
Cross-sectional study
n=1240 |
50.6% men.
Mean age 39.1 ± 10.1 years. |
Patient self-report and physician confirmation. |
74.2%
Lipohypertrophy 46%
Lipoatrophy 53.2% |
